Proactive15 Jul 2019 17:02
Article too long to post. Extract...
What the boss is saying
“The company believes it is making strong scientific and commercial progress across all its technology and product platforms,” said chief executive Stephen O’Hara, recently.
“With the manufacturing scale-up progressing for SweetBiotix and work on LPLDL certification as a product manufactured to pharmaceutical standard nearing completion (extending the opportunity into pharmaceutical sales), more products are entering the commercialisation phase.
“With current products winning awards for their science and product innovation and growing deal flow across international markets, the company is continuing to grow revenue streams across a broad deal pipeline.
“If most of these partners deliver on their forecasts, revenues will continue to grow in the months and years ahead.
“We are particularly pleased that, as the value of our brands increase internationally, we are seeing increased retail interest and a number of our larger corporate partners committing to product launches.
Blue sky
A couple of years ago, OptiBiotix spun out its skin division, SkinBioTherapeutics PLC (LON:SBTX) and listed it on AIM.
Going forward, the plan is to explore similar demergers with the other divisions.
“Part of the process is building up these divisions, creating a separate legal entity and putting those on the stock market,” said CEO O’Hara.
“We did that with SkinBioTherapeutics already, and what we’ll do is give our shareholders a dividend, or dividend in specie – we’ve always promised that we’ll do that.”
Trek
https://www.proactiveinvestors.co.uk/companies/news/223928/optibiotix-continuing-to-put-in-place-commercial-building-blocks-223928.html